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ORIGINAL ARTICLE
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Julie De Backera,d
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ABSTRACT
Background: Marfan syndrome (MFS) is a multisystemic hereditary connective tissue disease.
Aortic root aneurysms and dissections are the most common and life-threatening cardiovascular
disorders affecting these patients. Other cardiac manifestations include mitral valve prolapse,
ventricular dysfunction and arrhythmias. Medical treatment of cardiovascular features is ultim-
ately aimed at slowing down aortic root growth rate and preventing dissection. Losartan has
been proposed as a new therapeutic tool for this purpose. To which extent losartan affects car-
diac function has not been studied previously.
Methods: We designed a prospective, double-blind, randomized placebo-controlled trial to
evaluate the effect of losartan added to beta-blocker therapy on aortic growth and ventricular
function in patients with MFS. Secondary outcomes were aortic dissection, prophylactic aortic
surgery and death.
Results: Twenty-two patients were enrolled in the trial. There was a mild and similar increase in
the aortic root during the 3 years of follow-up in both groups (median 1mm, IQR [1–1.5] and
1mm, IQR [0.25–1] in the losartan and placebo group, respectively, p¼ 1). Diastolic and systolic
ventricular function was normal at baseline in both groups and remained stable during
the study. One patient in the placebo group presented a subclavian artery dissection during fol-
low-up.
Conclusion: Losartan on top of beta-blocker therapy has no additional effect on aortic growth
or on cardiac function in patients with MFS. Our results are underpowered but are in line with
the result from other groups. In order to have a better insight on whether a group of patients
could benefit more from losartan therapy, the outcome of an on-going meta-analysis should be
awaited.
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Introduction
Marfan syndrome (MFS) is a hereditary connective tis-
sue disorder occurring in approximately 1 in 5000 indi-
viduals [1]. It is a multisystemic disorder primarily
affecting the cardiovascular, ocular and skeletal organ
systems. Aortic aneurysms and dissections are the
most relevant and life-threatening cardiovascular mani-
festations related to MFS [2]. Mitral valve prolapse,
impaired ventricular function and arrhythmias are also
recognized in these patients [3–6].
The care for MFS patients has improved consider-
ably in the past decades leading to a significant
improvement in life expectancy [7]. Regular follow-up
to determine the need of prophylactic surgery,
restriction of static sports and treatment with beta
blockers have become the cornerstones of treatment
[8]. Despite good management and follow-up, how-
ever, aortic growth rate is still higher than in
unaffected individuals, and in some cases, dissection
occurs at lower diameters than expected. For this
reason, searching for better therapeutic strategies is
still necessary.
MFS is caused by mutations in the fibrillin 1 (FBN1)
gene (NM_000138.4) which encodes for the protein
fibrillin-1 [9]. Fibrillin-1 is the most important compo-
nent of the microfibrils and plays a crucial structural
and functional role in the extracellular matrix
(ECM). Fibrillin-1 is a fundamental element of the
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elastin-contractile unit [10] and of the microfibril scaf-
fold. This scaffold is one of the elements responsible
for the mechanosensing and mechanotransduction of
the ECM and affects transforming growth factor b
(TGFb) signalling [11]. In 2003, Neptune et al. [12]
showed marked upregulation of the TGFb pathway in
a MFS mouse model. This led to the hypothesis that
losartan, an angiotensin-II receptor I antagonist (ARB)
with a presumed TGFb-antagonizing effect could be
useful for the treatment of the disease. The first prom-
ising results in the Fbn1C1039G/þ mouse model showed
an aortic root growth rate in the MFS mice treated
with losartan that was similar to their wild-type (WT)
littermates and significantly lower in comparison with
untreated mice and mice treated with propranolol
[13]. Unfortunately, studies of losartan in monotherapy
in human patients failed to show the same promising
results [14,15].
Studies of losartan in addition to beta-blocker ther-
apy to evaluate whether this combined strategy could
achieve better results have also been conducted. Two
large European trials were performed: the COMPARE
(COzaar in Marfan Patients Reduces aortic
Enlargement) study and the Marfan Sartan study
[16,17]. The first study found a mild, but significant dif-
ference in aortic root growth rate between the beta-
blocker group and beta-blocker plus losartan group.
This result was, however, not confirmed in the Marfan
Sartan study. The methodology of these trials was
similar except for the blinding method and the imag-
ing technique used.
Based on the results of all the above-mentioned tri-
als, losartan is currently regarded as a valid alternative
in MFS patients who are intolerant to beta-blockers.
Another question is whether treatment with losar-
tan influences ventricular function in MFS patients.
Losartan has been shown to have a beneficial effect
on LV function in the Fbn1mgR/mgR mouse model [18].
Furthermore, it is known that patients with symptom-
atic heart failure can benefit from treatment with
losartan [19].
The aim of our study was to demonstrate whether
losartan added to beta-blocker therapy could influence
the aortic growth at different aortic levels and whether
it could improve ventricular function in these patients.
Methods
The Ghent Marfan trial is a prospective, double-blind,
randomized, placebo-controlled add-on trial comparing
losartan with placebo in patients with MFS in addition
to beta-blocker therapy. The study design was
previously published [20]. The study was reviewed and
approved by the local Independent Ethics Committee
(IEC) and the Institutional Review Board (IRB) of the
Ghent University hospital. All patients signed an
informed consent document before enrolling in the
trial. The study was registered on ClinicalTrials.gov
under the identifier NCT00782327.
Population
Inclusion criteria were age 10 years, an aortic root
z-score 2 and patients had to fulfil the revised Ghent
criteria. Patients intolerant to ARB, known with renal
artery stenosis or abnormal renal function, liver func-
tion abnormalities or heart failure, or planning preg-
nancy or breastfeeding, were excluded.
Stratified by a combination of gender, age and
z-score, patients were randomized in four permuted
blocks to receive losartan capsules or placebo capsules
for 36 months. The study medication was provided by
MSD Belgium (Merck, Sharp & Dohme). It was given at
an initial dose of 25 or 50mg and was uptitrated to a
maintenance dose of 50mg or 100mg to the patients
with a weight of < or  50 kg, respectively.
Study procedures
Clinical and echocardiographic assessment was
done at baseline and at 6, 12, 24 and 36 months.
Echocardiography was performed with a Vivid E7 (GE
Vingmed Ultrasound, Horten, Norway) ultrasound
machine and conventional techniques according to
the American Society of Echocardiography were used
for valvular and ventricular evaluation [21]. Aortic and
mitral valve regurgitation were graded into mild, mod-
erate or severe and all types of mitral valve prolapse
were considered. Z-scores for aortic root dilation were
calculated according to Devereux et al. [22]. For
detailed evaluation of systolic and diastolic function, a
combination of pulsed-wave and tissue Doppler imag-
ing and automated function imaging was used.
Cardiovascular MRI was performed at baseline and
at the end of the trial. A 3D T1 weighed spoiled gradi-
ent echo angiographic sequence was used to visualize
the entire aorta during intravenous administration of
0.1mmol/kg of gadolinium. Aortic measurements at
seven landmark levels (annulus, aortic root, sinotubular
junction, ascending and descending aorta at the level
of the right pulmonary artery, aortic arch and abdom-
inal aorta at the level of the diaphragm) were per-
formed (Figure 1). If any dilation or aneurysm was
detected between these levels, additional measure-
ments were taken. TrueFISP cine images of cardiac
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long-axis and short-axis stack for volume measurement
were performed to calculate ventricular volumes and
cardiac function. Post-processing took place on a
radiological workstation, ARGUS (Malvern, PA, USA)
analysis software.
Outcome
Primary end points were rate of aortic root growth,
ventricular chamber dilation and ventricular function.
Secondary end points were progression of aortic or
mitral regurgitation, aortic dissection, aortic root or
distal aortic surgery and death.
Statistical analysis
Statistical analysis was performed using IBM SPSS
Statistics 23 package (SPSS Inc., Chicago, IL). Normally
distributed data were analysed using the independent
sample, the paired-sample t-test and the repeated
measures ANOVA. Non-normally distributed data were
analysed using the Wilcoxon–Mann–Whitney, the non-
parametric related sample test and the Kruskal–Wallis
and Friedman tests for repeated measurements.
Logistic linear regression was used to calculate
adjusted variables. Correlations were analysed using
Spearman’s rank correlation. p values were considered
significant if equal to or less than .05.
Results
Population
Between November 2009 and July 2011, 22 patients
with MFS were enrolled in the trial. In all patients, an
underlying FBN-1 mutation was confirmed. All patients
except one were treated with beta blockers (10 aten-
olol, 7 bisoprolol, 2 metoprolol, 2 propranolol, 1
intolerant). Twelve were assigned to losartan and 10
were assigned to placebo. From the patients in the
losartan group, two did not finish the study: one due
to progressive aortic root growth on echocardiography
and one due to pregnancy. All the others completed
the study (Figure 2). Seven patients (5 in the placebo
group and 2 in the losartan group) had previous aortic
root replacement and were therefore not taken into
Figure 1. Magnetic resonance (MR) images of a Marfan patient: (A) aortic sinus multiplanar reconstruction (MPR) image of MR
angiography image data set; (B) aortic sinus cine image; (C) parasagittal MPR of the angiographic image data set, aligned with the
aorta (‘candy cane image’) showing four locations of imaging for PWV analysis (white dashed lines) and seven locations for per-
pendicular luminal diameter measurement (red dashed lines).
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consideration for measurements of the aortic root and
aorta ascendens.
Baseline
Baseline variables for both groups are shown in
Table 1. Mean age at recruitment was 35.4 years (95%
CI 24.2–46.6] and 36.83 years [95% IC 23.02–50.65]
years for the placebo and losartan group, respectively.
Clinical features, echocardiographic parameters and
measurements of MRI were similar in both groups.
Only systolic blood pressure differed significantly
among groups (143.1mmHg 95% CI [124–162.2] in
the placebo group versus 125.33mmHg 95% CI
[107.13–143.53] in the losartan group, p¼.038).
Primary outcomes
Aortic diameters
Aortic root dilation could be evaluated in 14 patients.
Figure 3 shows the evolution of the mean aortic root
diameter measured by echocardiography during the
time of follow-up. There was a mild but not significant
increase in aortic root diameter within the groups dur-
ing the 3 years of the study (p¼ .187 for the placebo
group and p¼ .169 for the losartan group). This
increase was not significantly different between the
groups (median 1mm, IQR [1–1.5] and 1mm, IQR
[0.25–1] in the losartan and placebo group, respect-
ively, p¼ 1). No difference between the groups was
observed on cardiac MRI (Table 2). Additionally, we did
not find significant growth at any of the other prede-
fined levels of the aorta on cardiac MRI in any of
the two groups (Table 2). These results remained non-
significant after adjusting for blood pressure.
In all but one patient with asymmetric aortic root,
there was a good correlation observed in measure-
ment of aortic root by echocardiography and cardiac
MRI (R2¼ 0.794; p¼ .001).
Ventricular chambers and ventricular function
Mild aortic valve regurgitation and mild mitral valve
regurgitation was present in 9 and 16 patients at base-
line, respectively. These cases of valvular regurgitation
were equally distributed between the placebo and los-
artan groups (Table 1). One patient in the losartan
group had moderate mitral valve regurgitation.
Ventricular function and chamber quantification on
MRI was available for 20 patients (10 in the placebo
and 10 in the losartan group). Results for both groups
are shown in Table 1. At baseline, left and right ven-
tricular ejection fractions (LVEF, RVEF) were normal
and similar in both groups. Left and right ventricular
function remained stable during the study (Figure 4).
Diastolic function measured by echocardiography was
also normal at baseline and remained normal in the
course of the study (Tables 1 and 2).
Secondary outcomes
Only one patient in the placebo group reached one of
the predefined secondary end points. She presented a
dissection of the right subclavian artery requiring
intervention.
Safety control
None of the patients of the losartan group experi-
enced clinical side effects. Total blood count, electro-
lytes, creatinine, alanine aminotransferase and
aspartate aminotransferase were checked at baseline
and 6 months after starting therapy. There was no dif-
ference in the blood levels of any of these parameters
between baseline and 6 months after starting therapy
and all values were normal.
Discussion
The Ghent Marfan trial was designed to study the
effect of losartan as add-on therapy on aortic root
growth and ventricular systolic and diastolic function
in patients with MFS. This study could not find an
Figure 2. Inclusion and randomization. FU: follow-up; y: years;
MFS: Marfan syndrome; BB: beta-blockers; AoRR: aortic root
replacement.
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effect on aortic root growth nor ventricular function
when losartan was added to beta-blocker therapy.
Even though underpowered, the results of our
study are in line with those previously reported in
larger patient groups [17]. In 2014, the Pediatric Heart
Network (PHN) published the first large randomized
study on the effect of losartan in comparison to aten-
olol in 608 paediatric and young adult MFS patients
[14]. In this study, there was no significant difference
in the rate of aortic root dilatation between the losar-
tan and the atenolol group. More recently, Forteza
et al. also published the results of a large randomized
trial comparing the effect of losartan versus atenolol
on aortic root and ascending aortic growth in adults
with MFS [15]. After 3 years of follow-up, there was a
significant increase in aortic root diameter in both
groups; however, there was no significant difference in
aortic root growth rate nor ascending aortic growth
rate between both groups.
Two recent European trials showed discrepant
results when losartan was added to beta-blocker ther-
apy for treating patients with MFS. The COMPARE was
a multicentre, open-label, randomized controlled trial
which included 233 MFS adult patients [16]. Aortic
root growth rate measured with MRI was significantly
lower in patients treated with added losartan com-
pared to patients treated with beta-blockers only.
No difference was found in the secondary end points
(aortic dissection, elective aortic surgery and cardiovas-
cular death). Another large European trial investigating
losartan added to beta-blocker therapy was the
‘Marfan Sartan’ trial [17], a multicentre, double-blind,
randomized controlled trial involving 303 MFS patients
older than 10 years. This study did not find a signifi-
cant effect of losartan on aortic root growth rate even
though losartan did achieve a significant reduction of
systolic and diastolic blood pressure. Although both
trials had a similar design, the COMPARE study was an
Table 1. Demographic and clinical characteristics of the population.
Placebo (n:10) Losartan (n:12) p value
General characteristics
Age 35.4 (11.20) 36.83 (13.81) .795
Male 6 (60%) 4 (33.3%) .391
Length (cm) 188.2 (177.4–198.9)a 182.5 (11.88) .257
Weight (kg) 80.2 (60.9–99.5)a 72.5 (13.68) .287
BMI (kg/m2) 22.52 (18.23–26.8)a 21.71 (3.05) .609
Heart rate (bpm) 63.5 (9.67) 60.91 (11.17) .689
SBP (mmHg) 143.1 (124.1–162.3)a 125.33 (18.2) .038b
DBP (mmHg) 75. 6 (66.6–84.6)a 74.5 (13.8) .629
AoR replacement 5 (50%) 2 (15.7%) .172
Echocardiographic parameters
Ao annulus (mm) 25.8 (1.09) 25 (3.5) .632
AoR (mm) 42 (2.5) 40.82 (3.86) .546
AoR z-score 3.48 (0.79) 3.57 (1.16) .869
ST-junction (mm) 35.4 (3.05) 33.2 (5.5) .432
Ao regurgitation 4 (40%) 5 (41.7%) .633
MVP 6 (60%) 8 (66.7%) 1.000
Mitral regurgitation 8 (80%) 9 (75%) .633
DT (ms) 185.4 (35.46) 182.92 (38.70) .878
E/A ratio 1.53 (0.54) 2.18 (1.15) .117
Septal E’/A’ ratio 1.24 (0.67) 1.25 (0.55) .973
Septal E/E’ ratio 9.27 (4.13) 10.05 (3.49) .650
Cardiac MRI parameters
Ao annulus (mm) 29.25 (1.5) 28.75 (4.00) .819
AoR (mm) 40 (3.20) 40.6 (5.27) .940
ST-junction (mm) 30 (2.34) 31.4 (2.18) .270
Ao ascendens (mm) 27 (26–32)a 28.3 (3.26) 1.000
Ao arch (mm) 24.4 (2.63) 23 (21.25–26)a .582
Ao descendens (mm) 24.3 (2.31) 26.5 (21.75–32)a .314
Ao abdominal (mm) 21 (19.75–24)a 19.5 (18–24.25)a .628
iLVEDvol (mL/m2) 91 (85.25–99)a 89.5 (75.5–92.75)a .418
iLVESvol (mL/m2) 30.3 (7.58) 25.58 (6.80) .140
iLVmass (gr/m2) 58.11 (13.06) 51.91 (12.19) .278
LVEF (%) 66.5 (5.03) 71.16 (6.08) .068
iRVEDvol (mL/m2) 85 (16.99) 80.33 (17.68) .530
iRVESvol (mL/m2) 31.5 (13.89) 28.5 (9.39) .554
RVEF (%) 59.3 (6.73) 65.16 (6.69) .055
aNon-parametric variables. Expressed as mean and interquartile range.
bStatistic significant value.
Ao: aortic/aorta; AoR: aortic root; BMI: body mass index; DBP: diastolic blood pressure; iLVEDvol: index left ventricular end-
diastolic volume; iLVEDvol: index left ventricular end-systolic volume; iRVEDvol: index right ventricular end-diastolic volume;
iRVESvol: index right ventricular end-systolic volume; SBP: systolic blood pressure; LVEF: left ventricular ejection fraction;
LVmass: left ventricular mass; MVP: mitral valve prolapse; RVEF: right ventricular ejection fraction; ST-junction: sino-tubular
junction.
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open-label trial with blinded assessment and the
Marfan Sartan study was a double-blind controlled
trial. Furthermore, the dose used in the studies dif-
fered considerably. In both trials, losartan was started
at a low dose and progressively increased to the max-
imum dose: 100mg in the COMPARE and 50mg or
100mg in the Marfan Sartan study depending on the
weight being above or below 50 kg. Only 54% of the
Figure 3. Mean aortic root diameter on echocardiography for all five time points in the losartan and in the placebo group. There
is no significant difference between the groups for any time point during the follow-up.
Table 2. Primary outcome.
Placebo Losartan p value Adjusted p value
Echocardigraphic parameters
AoR growth (mm/3 y) 1 (1–1.5) 1 (0.25–1) 1 .768
Change z-score/3 y 0.14 (0.52–0.40) 0.21 (0.32–0.30) .859 .642
Change DT (ms) 25.8 (69.50) 6.27 (63.82) .284 .085
Change E/A ratio 0.07 (0.36) 0.48 (0.79) .145 .214
Change septal E’/A’ 0.14 (0.32–0.06) 0.06 (0.30) .095 .083
Change septal E/E’ 0.04 (2.01) 0.2 (1.84) .852 .884
Cardiac MRI parameters
Ao annulus growth (mm/3 y) 0.0 (2.1) 0.37 (1.06) .688 .925
AoR growth (mm/3 y) 0.6 (2–0.5) 0.0 (1.5–0.5) .797 .495
ST-junction growth (mm/3 y) 0.0 (1–2.5) 1.5 (2–0.5) .622 .160
Ao ascendens growth (mm/3 y) 0.0 (0.0–1.0) 0.0 (0.5–1.0) .797 .630
Ao arch growth (mm/3 y) 0.0 (1.5–1.0) 1.0 (1.0–0.0) .426 .997
Ao descendens growth (mm/3 y) 0.7 ± 2.62 0.09 ± 1.64 .413 .529
Ao Abdominal growth (mm/3 y) 0.0 (1–1.25) 1.0 (1.0–0.0) .251 .248
Change iLVEDvol (mL/m2/3 y) 0.42 ± 7.41 1.75 ± 1.96 .595 .595
Change iLVESvol (mL/m2/3 y) 0.12 ± 6.33 0.25 ± 5.24 .961 .791
Change iLVmass (gr/m2/3 y) 51 (68.02; 43.75) 51 ± 28.21 .796 .981
Change LVEF (%/3yr) 0.19 ± 5.7 1.14 ± 5.65 .607 .856
Change iRVEDvol (mL/m2/3 y) 47.39 ± 9.78 52.25 ± 9.25 .269 .336
Change iRVESvol (mL/m2/3 y) 1.87 ± 4.25 0.5 (1.5–5.25) .328 .519
Change RVEF (%/3 y) 0.47 ± 5.33 1.55 (7.25–2.0) .353 .434
Non-parametric variables. Expressed as mean and interquartile range.p value adjusted for blood pressure.
AoR: aortic root; Ao: aortic/aorta; iLVEDvol: index left ventricular end-diastolic volume; iLVEDvol: index left ventricular end-systolic volume; LVEF: left ven-
tricular ejection fraction; LVmass: left ventricular mass; iRVEDvol: index right ventricular end-diastolic volume; iRVESvol: index right ventricular end-systolic
volume; MVP: mitral valve prolapse; RVEF: right ventricular ejection fraction; ST-junction: sino-tubular junction.
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patients in the COMPARE trial and 73% in the Marfan
Sartan trial completed the study with the previously
assigned dose of losartan. The remainder of the
included patients either took a reduced dose of losar-
tan or prematurely stopped treatment due to side
effects or intolerance. In which way this change in
therapy has influenced the results is difficult to meas-
ure. In our trial, we did not observe major side effects,
and therefore, all patients finished the trial according
to the initial agreed regimen. Another consideration is
the fact that although all patients met the revised
Ghent criteria, only 117 of the 233 patients included in
the COMPARE trial had a known mutation in FBN-1
gene. There is currently enough evidence of the
important clinical overlap between patients with differ-
ent syndromic forms of heritable thoracic aortic dis-
ease (H-TAD) [23,24], and therefore, some of the other
116 patients might have harboured a mutation in
another H-TAD gene. In the Marfan Sartan trial, 233
patients had a known FBN-1 gene mutation and 21
had a mutation in another H-TAD gene. To which
extent response to losartan varies among different
forms of H-TAD is not known. In our study, all patients
fulfilled the Ghent 2 criteria and harboured a causal
FBN-1 mutation.
Recently, a meta-analysis of all prospective random-
ized clinical trials studying the effect of losartan
on aortic dilation has been published [25]. This meta-
analysis included six different studies and found that
the rate of aortic dilation was significantly lower in the
losartan group (SMD¼0.13 95% CI [0.25–0.00],
p<.001). This result, however, should be interpreted
with caution: two of the six studies used for the meta-
analysis were a subgroup population of a bigger trial
and the design among them differed significantly.
Currently, there is a larger ongoing meta-analysis that
includes all the above-mentioned studies and some
other smaller studies [26]. The main aim of this meta-
analysis is to estimate the effect of ARB therapy and
beta-blocker therapy on change in aortic root size in
patients with no prior aortic root replacement across
the different studies. Subgroup analysis will also be
performed. The results of this meta-analysis will be
essential to determine whether a subgroup of patients
with MFS could benefit more than others from therapy
with losartan.
Next to aortic dilation, we also assessed cardiac
function in our study. Recent awareness of myocardial
involvement in patients with MFS manifesting with
ventricular dysfunction or arrhythmias has led to the
further investigation of these two entities. Abnormal
ventricular function has also been confirmed in two
different MFS mouse models (Fbn1mgR/mgR and
Fbn1C1039G/þ) [18,27]. These studies showed reduced
fibrillin-1 deposition in the ECM of myocardial tissue
and attributed this finding to the development of car-
diomyopathy. Deficiency of fibrillin-1 in the Fbn1mgR/
mgR mouse model affected the mechanical properties
of the myocardial tissue causing abnormal activation
of ERK 1/2 signalling through the stretch-stimulated
angiotensin 1 receptor/b-arrestin 2 pathway. These
findings were further confirmed by showing normalisa-
tion of cardiac size and function in the Fbn1mgR/mgR
mice after administration of losartan. Based on the
findings of these mouse models we studied whether
patients with MFS would also benefit from losartan
therapy. We were, however, not able to show this
effect. Both right and left ventricular parameters
remained stable during the course of the study.
Nevertheless, the average cardiac function in our
Figure 4. Left and right ventricular ejection fraction (LVEF, RVEF) at baseline and at the end of the study in both placebo and los-
artan groups. There is no significant change in cardiac function within the groups nor between the groups.
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cohort, both in the losartan and in the placebo group,
was normal at baseline, and therefore, observing an
additional effect of losartan might not be possible.
Our study was too small to analyse those patients
with mildly decreased ventricular function separately
which is necessary to fully understand the effect of
losartan on cardiac function in patients with MFS.
The major limitation of this study was the limited
amount of patients participating. Recruitment was
hampered by the fact that we already participated in
the PHN trial and had enrolled a significant amount of
patients in that trial that could not be included in this
one. Secondly, the patient community was very influ-
enced by the initial positive results obtained with los-
artan in MFS patients and therefore reluctant to
participate in a trial.
In conclusion, randomized studies of losartan for
the prevention of aortic dissection in patients with
MFS, ours included, have failed to show extra benefit
over beta blockers. The COMPARE trial showed a slight
but significant reduction of aortic root growth in the
losartan group in comparison to beta-blocker use
alone. Whether a specific subgroup of patients could
benefit more from losartan therapy still needs better
study. The results of an ongoing meta-analysis of all
randomized controlled losartan trials should be
awaited [26]. Until then losartan should be considered
as a safe and valuable alternative to beta-blocker
therapy.
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